Naringin (Flavanone Glycoside · CYP3A4 Inhibitor · Lipid-lowering)

Compound	Naringin (Naringenin-7-O-Neohesperidoside; 4′,5,7-Trihydroxyflavanone-7-neohesperidoside)
Chemical class	Polyphenol — Flavanone Glycoside (naringenin + neohesperidose disaccharide at C-7)
CAS	10236-47-2
Primary source	Citrus paradisi (grapefruit peel), Citrus maxima (pomelo), Citrus aurantium (bitter orange)
Key applications	CYP3A4/P-gp inhibition; lipid-lowering; bone health; anti-inflammatory
Claim strength	High (CYP interaction); Moderate (metabolic)
Typical form	Naringin 98% Powder (Pomelo; Citrus grandis); Grapefruit Extract Powder (naringin as primary flavanone)
Buy from Herbuno	Naringin 98% Powder (Pomelo) | High-Purity Isolate | Citrus grandis → Grapefruit Extract Powder →

Name origin: Naringin is named after Naringi — an old synonym for Citrus — and carries the neohesperidoside sugar that gives grapefruit its characteristic bitter taste. It is the 7-O-neohesperidoside of naringenin (naringenin + rhamnose-α1→2-glucose at C-7), and the bitter counterpart to the tasteless rutinoside hesperidin. The α-1→2 linkage of neohesperidose is responsible for the intense bitterness — contrasting with the β-1→6 linkage of rutinose (in hesperidin, naringenin rutinoside) which is tasteless. Traditional use: Grapefruit (Citrus paradisi) is a relatively modern Citrus cultivar (first documented 1750 in Barbados as a hybrid of pomelo and sweet orange) with no deep traditional medicinal history. Pomelo (Citrus maxima), however, has traditional use in Southeast Asian medicine for respiratory and digestive conditions and is the primary commercial source of naringin 98% extract. Bitter orange (Citrus aurantium, Zhi Ke/Zhi Shi) has extensive TCM use for digestive disorders and is another naringin-rich source. Research trajectory: Naringin is best known pharmacologically for its CYP3A4 and P-glycoprotein inhibitory effects — the mechanism behind the grapefruit-drug interaction affecting over 50 pharmaceutical drugs. This pharmacological interaction has both risk (unintended drug concentration elevation) and opportunity (intentional bioavailability enhancement) dimensions for formulators. Commercial source: Naringin 98% Powder (from Citrus grandis/pomelo) is available from Herbuno as a high-purity standardised isolate — one of the highest purity commercially available Citrus flavanone preparations.

---

Evidence for Naringin Applications

CYP3A4 and P-glycoprotein inhibition: Naringin and its aglycone naringenin inhibit intestinal CYP3A4 and P-glycoprotein (P-gp, MDR1/ABCB1) — the two primary barriers to oral drug bioavailability. The grapefruit juice interaction with drugs including felodipine, simvastatin, cyclosporine, tacrolimus, atorvastatin, and sildenafil is mechanistically attributed to furanocoumarins (bergamottin, DHB) primarily and naringin/naringenin secondarily. For formulators, this inhibition can be deliberately exploited to enhance bioavailability of co-formulated compounds (curcumin, resveratrol, coenzyme Q10) that have poor intrinsic absorption due to CYP3A4/P-gp efflux. Claim strength: High (drug interaction); Moderate (intentional bioavailability enhancement).

Lipid-lowering and metabolic: Naringin reduces total cholesterol, LDL, and triglycerides in hyperlipidaemic rodent models via HMG-CoA reductase modulation, PPAR-α activation (promoting fatty acid oxidation), and bile acid synthesis upregulation. Multiple small human studies with grapefruit consumption show modest lipid-lowering effects. A 6-week RCT with naringin supplementation in hyperlipidaemic adults demonstrated significant LDL and total cholesterol reduction. Claim strength: Moderate.

Bone health: Naringin has demonstrated osteogenic activity in osteoblast cell models — upregulating RUNX2, osteocalcin, and alkaline phosphatase while inhibiting osteoclast differentiation via RANKL pathway suppression. In ovariectomised rodent osteoporosis models, naringin at 50–100 mg/kg preserves bone mineral density and trabecular architecture. Human clinical data for bone protection are not yet available. Claim strength: Moderate.

Anti-inflammatory and antioxidant: NF-κB inhibition, COX-2 suppression, and TNF-α reduction in macrophage models at 10–50 μM. The neohesperidoside sugar at C-7 improves aqueous solubility compared to naringenin, facilitating delivery to inflammatory sites. Antioxidant activity is moderate (no catechol B-ring; single 4′-hydroxyl on B-ring). Claim strength: Moderate.

---

Dosage & Formulator Specification

The lipid-lowering RCT used naringin 600 mg/day for 6 weeks in hyperlipidaemic adults — the most directly translatable human dosing data. Grapefruit juice studies showing CYP3A4 inhibition used 200–300 mL juice (providing 100–200 mg naringin equivalent), with drug interaction data showing clinically significant effects even at one glass. For intentional bioavailability enhancement, 100–250 mg naringin per serving is typically used as a bioavailability co-factor alongside poorly absorbed compounds.

Herbuno's Naringin 98% Powder from pomelo is among the highest purity commercially available naringin preparations, enabling precise dosing. For lipid-lowering applications, 500–600 mg/day naringin is the evidence-based dose. For bioavailability enhancement applications (lower naringin doses with the primary active), 100–200 mg per serving is appropriate.

Naringin's intense bitterness (neohesperidoside sugar) requires taste masking for direct oral formulations — encapsulation, sweetener co-formulation, or enteric coating. Stable in solid dosage forms; aqueous stability is pH-dependent (optimal pH 4–7). Compatible with vitamin C (Citrus context) and plant sterols in cardiovascular formulas.

Critical drug interaction note for formulators: Products containing naringin ≥100 mg per serving should include labelling guidance regarding grapefruit drug interactions for consumers on CYP3A4-sensitive medications (statins, immunosuppressants, calcium channel blockers, anticoagulants). This is not a prohibition on use but a mandatory communication requirement for responsible supplement labelling.

---

Frequently Asked Questions — Naringin

What causes the grapefruit-drug interaction and how does naringin contribute?
The grapefruit-drug interaction is primarily caused by furanocoumarins (bergamottin and 6′,7′-dihydroxybergamottin) that irreversibly inhibit intestinal CYP3A4. Naringin and naringenin contribute reversible CYP3A4 and P-glycoprotein inhibition. The combination raises plasma concentrations of CYP3A4-sensitive drugs (simvastatin, felodipine, cyclosporine) by 2–10-fold depending on the drug, creating toxicity risk. Pomelo naringin (without furanocoumarins) has less interaction risk than grapefruit juice containing both furanocoumarins and naringin.

Can naringin be used deliberately to enhance bioavailability of supplement actives?
Yes — this is an established and legitimate formulation strategy. Naringin at 100–250 mg per serving has been shown to enhance plasma levels of co-administered curcumin, resveratrol, coenzyme Q10, and various pharmaceutical drugs by inhibiting intestinal CYP3A4 and P-gp. The key is disclosure in labelling and awareness that the same mechanism applies to any CYP3A4-sensitive drug the consumer may be taking concurrently.

How does naringin differ from naringenin?
Naringenin is naringin's aglycone — the flavanone without any sugar. Naringin (glycoside) has lower intrinsic lipophilicity and requires gut microbial neohesperidosidase cleavage for absorption. Naringenin (aglycone) has higher lipophilicity, better direct absorption, and stronger in vitro bioactivity in most assays. For CYP3A4 inhibition, naringenin is more potent per mole; for dosing accessibility and cost, naringin is the commercial choice.

What makes Herbuno's Naringin 98% Powder different from standard grapefruit extract?
Standard grapefruit extract is typically 25–40% naringin with accompanying furanocoumarins, other flavanones, and peel constituents. Naringin 98% isolate from pomelo is a high-purity single-compound preparation allowing precise dosing, free from furanocoumarins (pomelo peel contains minimal bergamottin compared to grapefruit), and suitable for pharmaceutical-grade supplement formulation where excipient purity standards are required.

Related compounds: Naringenin, Hesperetin, Hesperidin, Eriodictyol

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery